Navigation Links
SPO Returns to Revenue Generation
Date:4/11/2013

p>During 2013, SPO anticipates expanding other product opportunities currently under development and specifically its fitness watch - a new consumer wellness time-piece designed to measure overall daily activity level, especially useful for overweight and obese adults and children. This new and innovative product, already demonstrated to several retail category buyers, will include unique innovative features as well as being a fashionable time-piece to continuously measure the number of daily activities and calories burned against a recommended goal.

Braunold continued: "We see substantial opportunities to expand in the drugstore channel and beyond as we grow our product portfolio during 2013, particularly as our partner HoMedics looks to increase distribution worldwide via its extensive network in over 60 countries. We look forward to an exciting year ahead for the Company as our products enter the vast consumer wellness market, which in turn contributes to potentially increasing value for the SPO shareholders."

About SPO

SPO is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: medical care; sports and wellness; homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spoglobal.com

Forward Looking Statements

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and tha
'/>"/>

SOURCE SPO Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
2. Informex Returns To India In 2012
3. Technical Analysis on GNC Holdings and Walgreen: Drug Store Stocks Set to Provide Good Returns
4. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
5. RSB Spine, LLC Announces 2011 Revenue Growth
6. diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance
7. BioLife Solutions 2011 Revenue Up 33%
8. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
11. Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... Cynosure, Inc. (NASDAQ: CYNO ) today announced financial ... Revenues for the first quarter of 2011 increased 16 percent ... 2010.   Net loss for the first quarter of 2011 was ... a net loss of $2.8 million, or $0.22 per basic and ...
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced ... The net income for the first quarter ended ... loss of $14.1 million during the same period in 2010. ... was related primarily to the $34.2 million in collaboration revenue ...
... VIVUS, Inc. (Nasdaq: VVUS ), a ... products, today reported its financial results for the first quarter ended ... quarter ended March 31, 2011, VIVUS reported a net loss of ... loss of $18.8 million or $0.23 per share for the first ...
Cached Biology Technology:Cynosure Reports Financial Results for the First Quarter of 2011 2Cynosure Reports Financial Results for the First Quarter of 2011 3Cynosure Reports Financial Results for the First Quarter of 2011 4Cynosure Reports Financial Results for the First Quarter of 2011 5Cynosure Reports Financial Results for the First Quarter of 2011 6MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... of years ago are recorded at daily rate in ... X-ray microscope has revealed growth bands in plankton shells ... The results could allow scientists to chart short ... years ago. Plankton shells show features like tree ...
... available in German . ... loss of eye lashes and eye brows, susceptibility to infection ... lengthy. Many cancer patients suffer from the intense effects that ... subcutaneously or administered intravenously to halt the growth of tumors ...
... salvia magnesium acetate, is a phenolic acid compound ... of caffeic acid. Salvianolic acid B exerts strong ... improves energy metabolism against cerebral ischemia-reperfusion injuries. Dr. ... Xiangya Hospital, Central South University, China found that ...
Cached Biology News:Reading ancient climate from plankton shells 2Nano-dwarves turn tumor assassins 2Nano-dwarves turn tumor assassins 3
... from 2 mM sodium phosphate buffer, pH ... D is a major lysosomal aspartyl protease ... kDa proenzyme. Overexpression of cathepsin D in ... risk of relapse and metastasis. Cathepsin D ...
Acetate Plate Sealers 100/Box...
...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
Biology Products: